AQP4 and neuromyelitis optica: Immunization of AQP4 into mice with underlying immune dysfunction (enhanced B cell activating factor expression, mutations in CD95 or its ligand) might be a useful approach to study enhanced survival of AQP4-specific B cells and thus to determine if NMO disease manifestation is more frequent.